US biopharmaceutical company Pfizer Inc (NYSE:PFE) and its German partner BioNTech SE (Nasdaq:BNTX) said on Monday that a third shot of their COVID-19 vaccine has been shown to be effective in young children.
In a Phase 2/3 trial which took place at a time when Omicron was the predominant variant, vaccine efficacy was 80.3% in children aged 6 months to under 5 years of age.
A total of 1,678 children took part in the trial, receiving a third shot of the low-dose formulation at least two months after their second shot.
Pfizer and BioNTech plan to submit the new data to the US Food and Drug Administration (FDA) this week, with submissions to the European Medicines Agency (EMA) and other regulators to follow.
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion